Newsroom
Keep up with the latest news about Biomoda by subscribing to our newsletter (the sign up form is on the bottom right of this page). For media contact information please visit our contact page.
Latest Press Releases
- European Patent Office Grants Biomoda Patent — 01.24.2012 / 8:00 am
The European Patent Office (EPO) has granted Biomoda, Inc.’s patent application for using our proprietary CyPath® technology to detect cancer and pre-cancerous cells in body fluid and tissue samples. Titled “Composition and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenol) Porphine,” EPO patent 1364044 is similar to…
- Biomoda Files New Patent Application To Optimize CyPath® Assay — 11.02.2011 / 8:58 pm
Albuquerque, NM – Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) filed an application for a new U.S. Patent that refines the use of fluorescent microscopy to increase the accuracy, sensitivity and specificity of the CyPath® diagnostic assay for lung cancer. “This patent is based on a proprietary solid-state, diode-based light source for fluorescent microscopy…
- Shareholder Meeting — 09.05.2011 / 8:35 pm
Biomoda Shareholder Presentation Meeting Results of Shareholder Meeting Proposal 1 The Company’s stockholders elected four individuals to the Board of Directors. Name VotesFor Votes Withheld John J. Cousins 162,513,010 656,872 Maria Zannes 162,800,016 369,866 Lewis White 162,619,007 550,875 David Lambros 162,619,007 550,875 Proposal 2 The Company’s stockholders…
See all news »
President's Column
- July President’s Column — 07.31.2012 / 4:28 pm
In the July 2012 President’s Column, Biomoda President John Cousins discusses the importance of prevention and early detection in the battle against cancer and the national effort to control health care costs. We welcome questions from investors. Please submit questions to investor@biomoda.com. Early Detection Saves Lives and Money In the wake of the Supreme Court’s…
- June President’s Column — 06.29.2012 / 8:00 am
In the June 2012 President’s Column, Biomoda President John Cousins discusses the importance of the veterans’ health care system and its potential impact on Biomoda’s long-term strategy for commercialization of the CyPath® assay for lung cancer. We welcome questions from investors. Please submit questions to investor@biomoda.com. VA System Outscores the Marketplace in Several Indicators The…
- May President’s Column — 05.27.2012 / 9:07 pm
In the May 2012 President’s Column, Biomoda President John Cousins acknowledges the contributions military veterans have made to our research and discusses Department of Defense funding for lung cancer research. We welcome questions from investors. Please submit questions to investor@biomoda.com. Our Long-Term Commitment to Veterans As Memorial Day approaches, it is important that we all…
See all »
Upcoming Events
See all events »
